This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: NVIDIA, Netflix, Starbucks, Pfizer, Estee Lauder and Stryker
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVIDIA, Netflix, Starbucks, Pfizer, Estee Lauder and Stryker
Top Stock Reports for NVIDIA, Netflix & Starbucks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Netflix (NFLX) and Starbucks (SBUX).
Top Analyst Reports for PayPal, Comcast & Novartis
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PayPal (PYPL), Comcast (CMCSA) and Novartis (NVS).
Colfax (CFX) Q3 Earnings Beat Estimates, Fall Y/Y on Sales
by Zacks Equity Research
Colfax's (CFX) Q3 earnings reflect the impacts of poor product demand due to the pandemic, forex woes and a fall in margin. For Q4, it predicts a sequential rise in sales and earnings.
Stryker (SYK) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) third-quarter earnings reflect strong segmental performance.
Stryker (SYK) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 52.86% and 9.93%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Quidel (QDEL) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Quidel's (QDEL) fiscal third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.
Medical Products' Oct 29 Earnings Roster: SYK, BAX & More
by Trina Mukherjee
Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.
Stryker (SYK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) third-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Stryker (SYK) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Stryker (SYK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerner (CERN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at Diagnostics segment.
DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
Why the Earnings Surprise Streak Could Continue for Stryker (SYK)
by Zacks Equity Research
Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Aphria (APHA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Aphria's (APHA) fiscal first-quarter results are likely to reflect higher sales from medical and adult-use cannabis products.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment.
Robot-Assisted Surgery Gains Momentum Amid Coronavirus
by Trina Mukherjee
Let's keep a watch on potentially strong three MedTech stocks with respect to robotic-assisted surgery that have shown promise during the pandemic.
The Zacks Analyst Blog Highlights: Anheuser-Busch InBev, Gilead Sciences, Canadian National Railway, Stryker Corp and Goldman Sachs
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anheuser-Busch InBev, Gilead Sciences, Canadian National Railway, Stryker Corp and Goldman Sachs
Top Stock Reports for Anheuser-Busch, Gilead & Canadian National
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Anheuser-Busch InBev (BUD), Gilead Sciences (GILD) and Canadian National Railway (CNI).
Top Stock Reports for Novartis, Zoom Video & Caterpillar
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Novartis (NVS), Zoom Video Communications (ZM) and Caterpillar (CAT).
Stryker (SYK) Down 1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Stryker (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Booz Allen Hamilton, Microsoft, Stryker and NVIDIA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Booz Allen Hamilton, Microsoft, Stryker and NVIDIA
AI Craze Continues Unabated: 4 Stocks to Put on Your Watchlist
by Tirthankar Chakraborty
The AI market is poised to see 46.2% average annual growth between 2019 and 2025. Given such promising AI prospects, here're four AI stocks that investors should keep an eye on.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.